603896.SH
寿仙谷
SSE · Healthcare · Biotechnology · CN
CNY 14.78
−1.40%Year over year
Reported trailing growth
- Revenue
- -5.3%
- EBITDA
- —
- EBIT
- -34.4%
- EPS
- —
- Free cash flow
- +61.5%
- Operating cash flow
- -20.4%
Forward estimates
Based on analyst estimates
- Revenue
- -23.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.3%
- EBITDA
- -12.9%
- EBIT
- -23.2%
- Net income
- -59.7%
- EPS
- -60.2%
- Free cash flow
- +84.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026